Miiskin, a leading platform for online dermatology consultations, has been awarded the Innobooster Grant to further enhance its AI-driven skin disease triage and autonomous treatment capabilities. The funding underscores Miiskin’s innovative approach to leveraging artificial intelligence to revolutionize dermatological care.
“Winning the Innobooster is a testament to our commitment to revolutionizing dermatology care,”
said Jon Friis, Founder and CEO of Miiskin.
The grant will enable Miiskin to improve efficiency for dermatologists by minimizing manual tasks involved in diagnosing and treating acne, the most prevalent skin condition worldwide. The company’s new AI Engine is designed to provide individualized treatment plans for patients within just 60 seconds, streamlining the process for both patients and doctors.
“Our AI-assisted workflows are designed to empower patients and dermatologists alike, delivering fast, accurate, and scalable treatment options that can be approved by the dermatologist with a single click.”
said Jon
Transforming Dermatology with AI
The platform will combine medical-grade imaging with advanced large language model (LLM) technology to assess skin disease severity and skin type with 90% accuracy. It will also generate personalized treatment plans and follow-up recommendations, simplifying the consultation process. By reducing the manual workload, Miiskin aims to enhance patient outcomes and improve efficiency for healthcare providers.
Dr. Ryan Trowbridge, a board-certified dermatologist and Miiskin advisor, highlighted the collaborative nature of the AI-powered solution.
“Miiskin’s AI engine will quickly analyze data and provide insights, but the dermatologist will always retain final authority over patient care. It’s a tool that elevates efficiency and accuracy and could lead to more affordable and accessible care for patients, simplifies interactions for providers, and preserves the opportunity for the medical professional to layer on their own expertise.”
says Dr. Trowbridge
Miiskin has already supported thousands of consultations in the U.S., experiencing significant growth among both patients and healthcare providers. The company anticipates that the advancements enabled by the Innobooster Grant will allow it to treat millions of patients globally, reduce administrative burdens for doctors, prevent provider burnout, and expand access to dermatology care worldwide.
“One of the key advantages of Miiskin’s new AI-driven solution is that it will be designed to support—not replace—dermatologists in diagnosing and treating acne,”
says Dr. Trowbridge
Founded in 2022, Miiskin is a digital dermatology platform dedicated to providing accessible, effective, and affordable telehealth solutions. The company’s mission is to positively impact 100 million patients by 2040, ensuring that high-quality dermatology care is available to all.
